Akkermansia Muciniphila

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: weight digestion inflammation

Research Overview

Research on Akkermansia muciniphila has most intensively focused on metabolic health and gut barrier biology, with additional major efforts in immuno-oncology and, more recently, neurodegeneration. Across animal models and mechanistic studies, A. muciniphila is repeatedly linked to obesity, insulin resistance/type 2 diabetes, dyslipidemia, fatty liver phenotypes, and intestinal inflammation, consistent with its ecological niche as a mucin-degrading symbiont of the mucus layer. Mechanistic work has examined host–microbe signaling and barrier function (e.g., mucus layer interactions, epithelial integrity), immune modulation, and microbial metabolites (notably short-chain fatty acids such as propionate). Translational interest has also expanded into “next-generation probiotic” development, including defined cultivation conditions and non-viable preparations.

The strongest evidence supports a causal, beneficial role in metabolic disease models: controlled mouse studies show that administration of A. muciniphila can prevent or attenuate diet-induced obesity and associated metabolic complications, and that efficacy can be retained when grown in a synthetic medium compatible with human use. Notably, pasteurized (non-viable) A. muciniphila has been reported to enhance metabolic benefits in mice, and a specific outer-membrane protein (Amuc_1100) can engage host innate immune signaling (via TLR2) and partially recapitulate effects on gut barrier and metabolism, providing a plausible molecular mediator. In humans, early safety data for live or pasteurized preparations have been reported, while in cancer immunotherapy, prospective observational evidence in advanced NSCLC indicates baseline fecal A. muciniphila abundance is associated with improved response and survival independent of key clinical covariates, supporting its potential as a biomarker (though not yet establishing therapeutic causality). In Alzheimer’s disease research, patient associations (reduced A. muciniphila and propionate) and preclinical experiments suggest propionate and/or A. muciniphila administration can improve cognitive and mitochondrial phenotypes in AD models, but this remains earlier-stage compared with metabolic indications.

Key gaps include (i) larger, well-controlled human interventional trials to establish efficacy (not just safety) across indications, define clinically meaningful endpoints, and determine optimal dosing, duration, and formulation (live vs pasteurized vs purified components); (ii) clarification of context dependence and confounding in biomarker studies (e.g., antibiotic exposure, co-occurring taxa, diet, baseline microbiome structure), particularly in immunotherapy where high relative abundance under certain conditions has been linked to resistance; and (iii) deeper mechanistic resolution of strain-level diversity, host genetics, and metabolite-mediated pathways (e.g., SCFAs, indole derivatives) that may explain heterogeneous outcomes across diseases. Additional research is also needed on colonization dynamics and durability, long-term safety in diverse populations, and standardized manufacturing/quality controls for therapeutic development.

1. What conditions has Akkermansia muciniphila been studied for?

  • Metabolic disease: obesity, insulin resistance/type 2 diabetes-related phenotypes, dyslipidemia, and liver steatosis (including MAFLD).

  • Inflammation and gut barrier dysfunction: intestinal barrier integrity and intestinal inflammation/colitis (IBD-related contexts are mentioned).

  • Cancer immunotherapy response: response/resistance biomarkers for immune checkpoint inhibitors (ICIs), including NSCLC and hepatocellular carcinoma (HCC), especially in MAFLD-HCC.

  • Neurodegeneration: Alzheimer’s disease (AD), including links to short-chain fatty acids (SCFAs), particularly propionate.

  • Stress, anxiety, and cancer progression: psychological stress-associated dysbiosis, anxiety-like behavior, and breast tumor growth/cancer stemness (via SCFAs such as butyrate; A. muciniphila implicated as a key altered taxon).

  • General “multi-disease” associations: reviews in the provided abstracts explicitly list associations with obesity, diabetes, liver steatosis, inflammation, and response to cancer immunotherapies, and emphasize the field’s shift from correlation toward causality.

2. Does it work in treating those conditions? Summarize the evidence.

  • Obesity/insulin resistance/dyslipidemia (preclinical efficacy; limited human evidence)

    • Mouse studies: administration of A. muciniphila prevented development of obesity and associated complications in prior work referenced by the abstract, and in the described study reduced fat mass development, insulin resistance, and dyslipidemia.

    • Notably, pasteurized A. muciniphila enhanced efficacy versus live bacteria in mice in that study.

    • Mechanistic support: an outer membrane protein (Amuc_1100) interacted with Toll-like receptor 2 (TLR2), improved gut barrier, and partly recapitulated benefits in mice.

    • Human evidence: the same abstract reports that administration of live or pasteurized A. muciniphila grown on a synthetic medium was safe in humans, and a separate review notes a “human proof-of-concept trial” supporting causal relevance; however, the provided abstracts do not include detailed human efficacy outcomes (e.g., magnitude of weight loss or glycemic change).

  • Immune checkpoint inhibitor response (human biomarker evidence; causality not established in NSCLC abstract)

    • NSCLC cohort (n=338): baseline stool A. muciniphila was associated with higher objective response rates and improved overall survival in multivariate analyses, independent of PD-L1 expression, antibiotics, and performance status.

    • Important nuance: antibiotic use coincided with very high relative dominance of A. muciniphila (>4.8%) plus Clostridium and was associated with resistance to ICI in that dataset, suggesting context matters and “more” is not always better.

    • MAFLD-HCC mouse models: A. muciniphila administration ameliorated liver steatosis and attenuated tumor growth; combining A. muciniphila with anti-PD1 produced maximal tumor growth suppression in multiple mouse models.

    • Clinical correlation in HCC: low A. muciniphila levels correlated with PD1 resistance and poorer progression-free survival (associative, not proof of causation in humans).

  • Alzheimer’s disease (animal and mechanistic evidence; human association)

    • Human observation: AD patients had decreased A. muciniphila abundance and decreased propionic acid in feces and blood.

    • Mouse model: oral propionate supplementation improved cognition and influenced mitochondrial homeostasis pathways (DRP1 downregulation via GPR41; enhanced PINK1/PARKIN-mediated mitophagy via GPR43).

    • Mouse model prevention: administering A. muciniphila before disease onset improved cognition and mitochondrial-related measures.

    • Limitation: evidence is primarily preclinical for treatment/prevention; the abstract does not report human interventional outcomes for AD.

  • Stress/anxiety and breast cancer progression (preclinical reversal; clinical correlations)

    • In mice, psychological stress altered microbiota including A. muciniphila and reduced SCFAs (butyrate). Supplementation with active A. muciniphila, butyrate, or a high-fiber diet reversed oncogenic properties and anxiety-like behavior.

    • Clinical correlations: fecal A. muciniphila and serum butyrate were inversely correlated with tumoral Wnt/β-catenin signaling markers, poor prognosis, and negative mood in breast cancer patients (correlative).

  • IBD/colitis and barrier integrity (preclinical/observational within animal facilities)

    • The IBD abstract describes facility-dependent resistance to chemically induced colitis associated with increased epithelial barrier integrity markers and implicates microbiome members; the excerpt is truncated, so the specific causal role of A. muciniphila cannot be fully verified from the provided text alone.

3. What health benefits does it have?

  • Metabolic improvements: reduced fat mass gain, improved insulin resistance, and improved dyslipidemia in mice; modulation of urinary metabolomics and intestinal energy absorption were associated with these effects.

  • Gut barrier support: improved gut barrier function is specifically linked to Amuc_1100 (outer membrane protein) interacting with TLR2; multiple abstracts/reviews emphasize mucus-layer ecology and barrier relevance.

  • Immune modulation relevant to cancer therapy: in NSCLC, baseline A. muciniphila was associated with a “richer commensalism” and a more inflamed tumor microenvironment in a subset; in MAFLD-HCC mice, A. muciniphila reduced immunosuppressive cell populations (m-MDSCs, M2 macrophages) and increased T-cell infiltration/activation when combined with PD1 therapy.

  • Potential neuroprotective effects (preclinical): in AD models, A. muciniphila (and its metabolite propionate) improved cognition and markers of mitochondrial homeostasis (fission/mitophagy pathways via GPR41/GPR43 signaling in the propionate arm).

  • Potential benefits under psychological stress (preclinical): supplementation with A. muciniphila reversed stress-associated anxiety-like behavior and reduced breast tumor growth/cancer stemness in mice, in a mechanism linked to SCFAs (notably butyrate) and Wnt/β-catenin signaling.

4. Does it have any downsides or side effects?

  • Safety/tolerability (limited but supportive)

    • One abstract explicitly reports that administration of live or pasteurized A. muciniphila grown on a synthetic medium was safe in humans (no specific adverse event rates are provided in the abstract).

  • Context-dependent associations that could be interpreted as “downsides”

    • In the NSCLC ICI cohort, antibiotic use coincided with relative dominance of A. muciniphila (>4.8%) plus Clostridium, and this pattern was associated with resistance to ICI. This does not prove A. muciniphila causes resistance, but it cautions that abundance and clinical context (e.g., antibiotics, co-occurring taxa) may matter.

  • Evidence gaps

    • Most efficacy data in the provided abstracts are from animal models; human interventional efficacy and long-term safety across populations (e.g., immunocompromised individuals) are not established here.

    • Because A. muciniphila is a mucin-degrading bacterium, theoretical concerns are sometimes discussed in the broader literature about mucus dynamics, but the provided abstracts emphasize barrier improvement rather than harm and do not report mucus-barrier adverse effects.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not directly evaluate host genetic variants that modify response or risk (i.e., no explicit pharmacogenomic findings such as SNP-by-treatment interactions).

  • Mechanistic “genetics-adjacent” signals (not pharmacogenomics): one abstract identifies a bacterial protein (Amuc_1100) acting through TLR2, implying that host innate immune signaling pathways could influence response, but no human genotype data are presented.

  • Receptor-mediated effects: the AD abstract links propionate’s effects to GPR41 and GPR43 signaling and mitochondrial pathways (DRP1, PINK1/PARKIN). This suggests plausible gene-pathway relevance, but the abstract does not test whether genetic variants in these receptors/pathways alter outcomes.

  • Clinical implication: at present, based on these abstracts alone, there is insufficient evidence to recommend A. muciniphila (or its components/metabolites) differently for specific genotypes.

References

  1. Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms.
    Patrice D Cani, Clara Depommier, Muriel Derrien, Amandine Everard, Willem M de Vos (2022) - Nature reviews. Gastroenterology & hepatology
  2. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice.
    Hubert Plovier, Amandine Everard, Céline Druart, Clara Depommier, Matthias Van Hul, Lucie Geurts, Julien Chilloux, Noora Ottman, Thibaut Duparc, Laeticia Lichtenstein, Antonis Myridakis, Nathalie M Delzenne, Judith Klievink, Arnab Bhattacharjee, Kees C H van der Ark, Steven Aalvink, Laurent O Martinez, Marc-Emmanuel Dumas, Dominique Maiter, Audrey Loumaye, Michel P Hermans, Jean-Paul Thissen, Clara Belzer, Willem M de Vos, Patrice D Cani (2017) - Nature medicine
  3. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.
    Lisa Derosa, Bertrand Routy, Andrew Maltez Thomas, Valerio Iebba, Gerard Zalcman, Sylvie Friard, Julien Mazieres, Clarisse Audigier-Valette, Denis Moro-Sibilot, François Goldwasser, Carolina Alves Costa Silva, Safae Terrisse, Melodie Bonvalet, Arnaud Scherpereel, Hervé Pegliasco, Corentin Richard, François Ghiringhelli, Arielle Elkrief, Antoine Desilets, Felix Blanc-Durand, Fabio Cumbo, Aitor Blanco, Romain Boidot, Sandy Chevrier, Romain Daillère, Guido Kroemer, Laurie Alla, Nicolas Pons, Emmanuelle Le Chatelier, Nathalie Galleron, Hugo Roume, Agathe Dubuisson, Nicole Bouchard, Meriem Messaoudene, Damien Drubay, Eric Deutsch, Fabrice Barlesi, David Planchard, Nicola Segata, Stéphanie Martinez, Laurence Zitvogel, Jean-Charles Soria, Benjamin Besse (2022) - Nature medicine
  4. Akkermansia muciniphila: biology, microbial ecology, host interactions and therapeutic potential.
    Athanasia Ioannou, Maryse D Berkhout, Sharon Y Geerlings, Clara Belzer (2025) - Nature reviews. Microbiology
  5. Akkermansia muciniphila and its metabolite propionic acid maintains neuronal mitochondrial division and autophagy homeostasis during Alzheimer's disease pathologic process via GPR41 and GPR43.
    Zifan Wang, Cai Wang, Boyu Yuan, Li Liu, Haoming Zhang, Mingqiang Zhu, Hongxia Chai, Jie Peng, Yanhua Huang, Shuo Zhou, Juxiong Liu, Liyong Wu, Wei Wang (2025) - Microbiome
  6. Akkermansia muciniphila as a Next-Generation Probiotic in Modulating Human Metabolic Homeostasis and Disease Progression: A Role Mediated by Gut-Liver-Brain Axes?
    Huafeng Jian, Yating Liu, Xiaoming Wang, Xinyang Dong, Xiaoting Zou (2023) - International journal of molecular sciences
  7. Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis.
    Yong Rao, Zhiqi Kuang, Chan Li, Shiyao Guo, Yaohao Xu, Dandan Zhao, Yutao Hu, Bingbing Song, Zhi Jiang, Zhenhuang Ge, Xiyuan Liu, Chengdao Li, Shuobin Chen, Jiming Ye, Zhishu Huang, Yongjun Lu (2021) - Gut microbes
  8. Akkermansia muciniphila induces intestinal adaptive immune responses during homeostasis.
    Eduard Ansaldo, Leianna C Slayden, Krystal L Ching, Meghan A Koch, Natalie K Wolf, Damian R Plichta, Eric M Brown, Daniel B Graham, Ramnik J Xavier, James J Moon, Gregory M Barton (2019) - Science (New York, N.Y.)
  9. A next generation probiotic,Akkermansia muciniphila
    Qixiao Zhai, Saisai Feng, Narbad Arjan, Wei Chen (2019)
  10. Akkermansia muciniphila: A promising probiotic against inflammation and metabolic disorders.
    Yanqing Zhao, Huijun Yang, Peng Wu, Shuguo Yang, Wenkun Xue, Biao Xu, Sirui Zhang, Bin Tang, Daoxiu Xu (2024) - Virulence
  11. Quercetin-Driven Akkermansia Muciniphila Alleviates Obesity by Modulating Bile Acid Metabolism via an ILA/m
    Jiaqi Liu, Youhua Liu, Chaoqun Huang, Chuan He, Tongyudan Yang, Ruiti Ren, Zimeng Xin, Xinxia Wang (2025) - Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  12. Akkermansia muciniphila: a potential candidate for ameliorating metabolic diseases.
    Huifang Niu, Minfeng Zhou, Daniel Zogona, Zheng Xing, Ting Wu, Rui Chen, Dandan Cui, Fengxia Liang, Xiaoyun Xu (2024) - Frontiers in immunology
  13. Abelmoschus manihot polysaccharide fortifies intestinal mucus barrier to alleviate intestinal inflammation by modulating Akkermansia muciniphila abundance.
    Yumeng Wang, Chengxi Li, Jianping Li, Shu Zhang, Qinyu Zhang, Jinao Duan, Jianming Guo (2024) - Acta pharmaceutica Sinica. B
  14. Intestinal Akkermansia muciniphila complements the efficacy of PD1 therapy in MAFLD-related hepatocellular carcinoma.
    Xue Qian Wu, Fan Ying, Katherine Po Sin Chung, Carmen Oi Ning Leung, Rainbow Wing Hei Leung, Karl Kam Hei So, Martina Mang Leng Lei, Wing Ki Chau, Man Tong, Jun Yu, Dai Wei, William Chi Shing Tai, Stephanie Ma, Yin Ying Lu, Terence Kin Wah Lee (2025) - Cell reports. Medicine
  15. The Role of Next-Generation Probiotics in Obesity and Obesity-Associated Disorders: Current Knowledge and Future Perspectives.
    Natalia G Vallianou, Dimitris Kounatidis, Dimitrios Tsilingiris, Fotis Panagopoulos, Gerasimos Socrates Christodoulatos, Angelos Evangelopoulos, Irene Karampela, Maria Dalamaga (2023) - International journal of molecular sciences
  16. Gut-derived lactic acid enhances tryptophan to 5-hydroxytryptamine in regulation of anxiety via
    Miaomiao Pan, Chenglang Qian, Shaoye Huo, Yuchen Wu, Xinyi Zhao, Yueming Ying, Boyu Wang, Hao Yang, Anaguli Yeerken, Tongyao Wang, Mengwei Fu, Lihong Wang, Yuhuan Wei, Yunhua Zhao, Chunhai Shao, Huijing Wang, Chao Zhao (2025) - Gut microbes
  17. Akkermansia muciniphila in neuropsychiatric disorders: friend or foe?
    Wenhui Lei, Yiwen Cheng, Jie Gao, Xia Liu, Li Shao, Qingming Kong, Nengneng Zheng, Zongxin Ling, Weiming Hu (2023) - Frontiers in cellular and infection microbiology
  18. Gut dysbiosis conveys psychological stress to activate LRP5/β-catenin pathway promoting cancer stemness.
    Bai Cui, Huandong Luo, Bin He, Xinyu Liu, Dekang Lv, Xiaoyu Zhang, Keyu Su, Sijia Zheng, Jinxin Lu, Cenxin Wang, Yuqing Yang, Zhuoran Zhao, Xianxian Liu, Xu Wang, Yingrui Zhao, Xiaoshan Nie, Yuanyuan Jiang, Ziyu Zhang, Congcong Liu, Xinyi Chen, Anqi Cai, Zhumeng Lv, Zhihang Liu, Fan An, Yunkun Zhang, Qiulong Yan, Keith W Kelley, Guowang Xu, Lingzhi Xu, Quentin Liu, Fei Peng (2025) - Signal transduction and targeted therapy
  19. Akkermansia muciniphila and Parabacteroides distasonis synergistically protect from colitis by promoting ILC3 in the gut.
    Joana Gaifem, Ana Mendes-Frias, Mathis Wolter, Alex Steimle, Maria Jose Garzón, Carles Ubeda, Clarisse Nobre, Abigail González, Salomé S Pinho, Cristina Cunha, Agostinho Carvalho, António Gil Castro, Mahesh S Desai, Fernando Rodrigues, Ricardo Silvestre (2024) - mBio
  20. Akkermansia muciniphilaplays critical roles in host health
    Qixiang Zhao, Jiadong Yu, Yan Hao, Hong Zhou, Yawen Hu (2023)


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!